Among children under age 5 years with acute gastroenteritis, Lactobacillus reuteri DSM 17938 as an adjunct to rehydration therapy did not reduce the duration of diarrhea compared with placebo.
Ongoing treatment with bisphosphonate therapy may not be needed to prevent future fractures in certain patients due to the sustained effect of the drug.
Findings seen among people with dystonia or spasticity treated with botulinum toxin type A.
Omalizumab rescue therapy produced rapid results in a patient with refractory status asthmaticus.
The probiotic Lactobacillus reuteri DSM17938 may be useful for managing colic in breastfed infants; however, its efficacy in formula-fed infants is unclear.
Researchers and pain experts formulated guidelines for the use of onabotulinumtoxinA for the management of chronic migraine.
Newly approved treatment options for axillary hyperhidrosis give more opportunities for clinicians to provide personalized treatment for patients.
Promising results for VX-659-, VX-445-tezacaftor-ivacaftor for cystic fibrosis with mutations in CFTR.
Olaparib, may help to improve duration of good quality of life and quality-adjusted progression-free survival in germline BRCA1/2-mutated ovarian cancer.
Overall response of platelet count 50,000/L seen in 43% of patients.
